Krystal Biotech Reports Strong Q3 2025 Performance

Krystal Biotech, Inc. ( (KRYS) ) has released its Q3 earnings. Here is a breakdown of the information Krystal Biotech, Inc. presented to its investors.

Krystal Biotech, Inc. is a global biotechnology company focused on developing genetic medicines for serious and rare diseases, with a strong emphasis on dermatology and respiratory conditions.

In its third-quarter 2025 earnings report, Krystal Biotech announced significant revenue growth, driven by the successful launch of its flagship product, VYJUVEK, in multiple international markets. The company also highlighted its robust financial position and ongoing advancements in its diverse pipeline of genetic therapies.

Key financial metrics revealed a net product revenue of $97.8 million for the quarter, marking a substantial increase from the previous year. The company maintained a strong gross margin of 96% and ended the quarter with $864.2 million in cash and investments. Strategic expansions included the launch of VYJUVEK in Germany, France, and Japan, alongside FDA approval for an updated U.S. label that broadens the eligible patient population.

Krystal Biotech is actively advancing its pipeline with several promising candidates in various stages of clinical trials, including treatments for cystic fibrosis, alpha-1 antitrypsin deficiency, and neurotrophic keratitis. The company is also preparing regulatory filings in the UK and Switzerland, aiming to expand its market reach further.

Looking ahead, Krystal Biotech is poised for continued growth, supported by its strong financial foundation and strategic focus on expanding access to its innovative therapies. The management remains optimistic about future developments and the potential impact of its genetic medicines on patient care worldwide.